2.3%

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual MeetingApplied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

 Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through…

20 hours ago
Colliers: About 80-85% of office leasing is expected in green-certified buildings; Green office inventory to reach ~ 700 million sq ft in next 2-3 yearsColliers: About 80-85% of office leasing is expected in green-certified buildings; Green office inventory to reach ~ 700 million sq ft in next 2-3 years

Colliers: About 80-85% of office leasing is expected in green-certified buildings; Green office inventory to reach ~ 700 million sq ft in next 2-3 years

Green building adoption accelerating across real estate segments, led by energy savings, rental premiums and emission reductionsGreen building footprint on…

1 month ago
Silynxcom Announces New Order from Israel Defense Forces – Total IDF Orders Surpass $2.3 Million Since Q3 2024Silynxcom Announces New Order from Israel Defense Forces – Total IDF Orders Surpass $2.3 Million Since Q3 2024

Silynxcom Announces New Order from Israel Defense Forces – Total IDF Orders Surpass $2.3 Million Since Q3 2024

Netanya, Israel, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and…

5 months ago
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MNDMediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

December 05, 2024 18:00 ET | Source: MediciNova, Inc. LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc.,…

5 months ago
Sonata Software: Q2’25 International Services revenue of $84.6 Mn, growth of 2.3% QoQ and Domestic Business delivered Gross Contribution of INR 70.2 Cr, growth of 2.5% QoQ. Invest verticals of BFSI & HLS rose 30% QoQ, offsetting the slowdown in Retail & TMT verticalsSonata Software: Q2’25 International Services revenue of $84.6 Mn, growth of 2.3% QoQ and Domestic Business delivered Gross Contribution of INR 70.2 Cr, growth of 2.5% QoQ. Invest verticals of BFSI & HLS rose 30% QoQ, offsetting the slowdown in Retail & TMT verticals

Sonata Software: Q2’25 International Services revenue of $84.6 Mn, growth of 2.3% QoQ and Domestic Business delivered Gross Contribution of INR 70.2 Cr, growth of 2.5% QoQ. Invest verticals of BFSI & HLS rose 30% QoQ, offsetting the slowdown in Retail & TMT verticals

MUMBAI, India, Nov. 6, 2024 /PRNewswire/ -- Sonata Software (NSE: SONATSOFTW) (BSE: 532221), a leader in Modernization Engineering, today reported…

6 months ago
Sonata Software: Q2’25 International Services revenue of $84.6 Mn, growth of 2.3% QoQ and Domestic Business delivered Gross Contribution of INR 70.2 Cr, growth of 2.5% QoQ. Invest verticals of BFSI & HLS rose 30% QoQ, offsetting the slowdown in Retail & TMT verticalsSonata Software: Q2’25 International Services revenue of $84.6 Mn, growth of 2.3% QoQ and Domestic Business delivered Gross Contribution of INR 70.2 Cr, growth of 2.5% QoQ. Invest verticals of BFSI & HLS rose 30% QoQ, offsetting the slowdown in Retail & TMT verticals

Sonata Software: Q2’25 International Services revenue of $84.6 Mn, growth of 2.3% QoQ and Domestic Business delivered Gross Contribution of INR 70.2 Cr, growth of 2.5% QoQ. Invest verticals of BFSI & HLS rose 30% QoQ, offsetting the slowdown in Retail & TMT verticals

MUMBAI, India, Nov. 6, 2024 /PRNewswire/ -- Sonata Software (NSE: SONATSOFTW) (BSE: 532221), a leader in Modernization Engineering, today reported…

6 months ago